Merck (MRK) said the U.S. FDA approved LIPFENDRA (enlicitide) tablets, the first and only once-daily oral PCSK9 inhibitor for adults with hypercholesterolemia, including HeFH. The approval is a clear positive regulatory milestone that expands Merck’s lipid-management franchise and could support future revenue growth.
Merck (MRK) said the U.S. FDA approved LIPFENDRA (enlicitide) tablets, the first and only once-daily oral PCSK9 inhibitor for adults with hypercholesterolemia, including HeFH. The approval is a clear positive regulatory milestone that expands Merck’s lipid-management franchise and could support future revenue growth.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
strongly positive
Sentiment Score
0.70
Ticker Sentiment
